CO2021017772A2 - Virus del dengue atenuados - Google Patents

Virus del dengue atenuados

Info

Publication number
CO2021017772A2
CO2021017772A2 CONC2021/0017772A CO2021017772A CO2021017772A2 CO 2021017772 A2 CO2021017772 A2 CO 2021017772A2 CO 2021017772 A CO2021017772 A CO 2021017772A CO 2021017772 A2 CO2021017772 A2 CO 2021017772A2
Authority
CO
Colombia
Prior art keywords
modified
recoded
flaviviruses
dengue virus
regions
Prior art date
Application number
CONC2021/0017772A
Other languages
English (en)
Inventor
Steffen Mueller
John Robert Coleman
Charles Stauft
Ying Wang
Original Assignee
Codagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codagenix Inc filed Critical Codagenix Inc
Publication of CO2021017772A2 publication Critical patent/CO2021017772A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona Flavivirus modificados, tales como un virus del dengue modificado de tipo 1, 2, 3, 4, una combinación de éstos, o una combinación tetravalente de éstos. La modificación según diversos aspectos de la invención da lugar a una reducción de la expresión de la proteína viral en comparación con un virus parental, en donde la reducción de la expresión es el resultado de la recodificación de una o más regiones del virus. Por ejemplo, puede recodificarse la región prM, o la región de la envoltura (E). En diversas realizaciones, una o más regiones se recodifican reduciendo el sesgo de pares de codones o el sesgo de uso de codones de la secuencia de codificación de proteínas. Estos Flavivirus modificados se utilizan como composiciones de vacunas para proporcionar una respuesta inmunitaria protectora.
CONC2021/0017772A 2019-06-25 2021-12-24 Virus del dengue atenuados CO2021017772A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962866477P 2019-06-25 2019-06-25
PCT/US2020/039166 WO2020263850A1 (en) 2019-06-25 2020-06-23 Attenuated dengue viruses

Publications (1)

Publication Number Publication Date
CO2021017772A2 true CO2021017772A2 (es) 2022-04-19

Family

ID=74060347

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017772A CO2021017772A2 (es) 2019-06-25 2021-12-24 Virus del dengue atenuados

Country Status (15)

Country Link
US (1) US20220347285A1 (es)
EP (1) EP3990014A4 (es)
JP (1) JP2022540773A (es)
CN (1) CN114302738A (es)
AU (1) AU2020307532A1 (es)
BR (1) BR112021026201A8 (es)
CA (1) CA3145401A1 (es)
CL (1) CL2021003475A1 (es)
CO (1) CO2021017772A2 (es)
CR (1) CR20210677A (es)
DO (1) DOP2021000271A (es)
IL (1) IL289274A (es)
MX (1) MX2022000038A (es)
PE (1) PE20220296A1 (es)
WO (1) WO2020263850A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587084C (en) * 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
BR112017004452B1 (pt) * 2014-09-05 2023-12-12 The Research Foundation For The State University Of New York Vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
EP3355899A4 (en) * 2015-09-30 2019-04-03 Ramot at Tel-Aviv University Ltd. In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS
KR20180127397A (ko) * 2016-03-11 2018-11-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생약독화된 지카 바이러스 백신
AU2018411586A1 (en) * 2018-03-08 2020-09-03 Codagenix Inc. Attenuated flaviviruses

Also Published As

Publication number Publication date
CR20210677A (es) 2022-04-26
BR112021026201A2 (pt) 2022-02-15
WO2020263850A1 (en) 2020-12-30
JP2022540773A (ja) 2022-09-20
CL2021003475A1 (es) 2023-01-06
MX2022000038A (es) 2022-02-24
BR112021026201A8 (pt) 2022-05-10
CA3145401A1 (en) 2020-12-30
EP3990014A1 (en) 2022-05-04
AU2020307532A1 (en) 2022-01-27
US20220347285A1 (en) 2022-11-03
IL289274A (en) 2022-02-01
DOP2021000271A (es) 2022-04-18
CN114302738A (zh) 2022-04-08
PE20220296A1 (es) 2022-03-07
EP3990014A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
PH12020551355A1 (en) Attenuated flaviviruses
PE20191362A1 (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este
PH12018502175A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
CO2019014677A2 (es) Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos
ES2676542T3 (es) Composiciones de CDV recombinante y usos de las mismas
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
AR118850A1 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
CR20220501A (es) Composiciones y métodos para la inducción de una respuesta inmune
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
AR121066A1 (es) Mutante de fimh, composiciones que lo contienen y uso del mismo
NI202000071A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
BR112022001912A2 (pt) Composições celulares compreendendo vetores virais e métodos de tratamento
CO2021017772A2 (es) Virus del dengue atenuados
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
PH12021550785A1 (en) Virus vaccine
EA201790778A1 (ru) Фармацевтические композиции длительного действия от гепатита с
MX2022013814A (es) Tratamiento de infecciones virales.
MX2019002696A (es) Metodos para tratar o prevenir una infeccion del virus del zika.
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид